Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 2
1979 1
1980 1
1981 23
1982 5
1983 29
1984 29
1985 24
1986 17
1987 55
1988 33
1989 40
1990 37
1991 42
1992 41
1993 29
1994 41
1995 44
1996 20
1997 38
1998 29
1999 28
2000 40
2001 37
2002 34
2003 39
2004 28
2005 29
2006 33
2007 26
2008 27
2009 27
2010 27
2011 18
2012 26
2013 24
2014 18
2015 30
2016 11
2017 18
2018 21
2019 18
2020 23
2021 18
2022 21
2023 22
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,186 results

Results by year

Filters applied: . Clear all
Page 1
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial.
Wardlaw JM, Woodhouse LJ, Mhlanga II, Oatey K, Heye AK, Bamford J, Cvoro V, Doubal FN, England T, Hassan A, Montgomery A, O'Brien JT, Roffe C, Sprigg N, Werring DJ, Bath PM; Lacunar Intervention Trial-2 (LACI-2) Investigator Group. Wardlaw JM, et al. JAMA Neurol. 2023 Jul 1;80(7):682-692. doi: 10.1001/jamaneurol.2023.1526. JAMA Neurol. 2023. PMID: 37222252 Free PMC article. Clinical Trial.
OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilostazol treatment on vascular, functional, and cognitive outcomes in patients with lacunar stroke. ...Compared with those participants not recei …
OBJECTIVE: To test the feasibility, drug tolerability, safety, and effects of 1-year isosorbide mononitrate (ISMN) and cilosta …
Isosorbide 5-mononitrate pharmacokinetics.
Chasseaud LF. Chasseaud LF. Cardiology. 1987;74 Suppl 1:6-11. doi: 10.1159/000174255. Cardiology. 1987. PMID: 3300979 Review.
Isosorbide 5-mononitrate differs from other clinically used organic nitrate vasodilators because of its almost complete oral absorption, the low intersubject variability in its plasma concentrations and pharmacokinetic parameters, its relatively long half-lif
Isosorbide 5-mononitrate differs from other clinically used organic nitrate vasodilators because of its almost complete
Pharmacokinetics of isosorbide mononitrate.
Abshagen UW. Abshagen UW. Am J Cardiol. 1992 Nov 27;70(17):61G-66G. doi: 10.1016/0002-9149(92)90028-w. Am J Cardiol. 1992. PMID: 1449102 Review.
Pharmacokinetic studies show that isosorbide mononitrate is rapidly absorbed after oral administration, reaches peak concentrations within an hour, undergoes no significant first-pass metabolism, and is virtually 100% bioavailable. ...Only 1-2% of an orally administ …
Pharmacokinetic studies show that isosorbide mononitrate is rapidly absorbed after oral administration, reaches peak concentra …
Long-acting isosorbide mononitrate.
Prakash A, Markham A. Prakash A, et al. Drugs. 1999 Jan;57(1):93-9; discussion 100. doi: 10.2165/00003495-199957010-00008. Drugs. 1999. PMID: 9951954 Review.
The antianginal effects of once-daily isosorbide mononitrate EL 50 to 100mg were generally similar to those of conventional isosorbide mononitrate or isosorbide dinitrate 10 to 20mg twice or 3 times daily, or sustained-release nifedipine 20mg twice or …
The antianginal effects of once-daily isosorbide mononitrate EL 50 to 100mg were generally similar to those of conventional …
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Redfield MM, et al. N Engl J Med. 2015 Dec 10;373(24):2314-24. doi: 10.1056/NEJMoa1510774. Epub 2015 Nov 8. N Engl J Med. 2015. PMID: 26549714 Free PMC article. Clinical Trial.
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. ...During all dose regimens, …
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. …
Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann W. Schaumann W. Int J Clin Pharmacol Ther Toxicol. 1989 Sep;27(9):445-53. Int J Clin Pharmacol Ther Toxicol. 1989. PMID: 2681004 Review.
ISDN is metabolized to isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN) which are pharmacologically active. ...
ISDN is metabolized to isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN) which are pharmacologi …
Isosorbide mononitrate for cervical ripening during labour induction: A systematic review and meta-analysis of 23 randomized controlled trials.
Abu-Zaid A, Alshahrani MS, Al-Matary A, Khadawardi K, Miski NT, Abuzaid M, Alrasheed MA, Baradwan A, Salem A, Salem R, Albadawi MI, Jamjoom MZ, Almubarki AA, Abdulmalik NA, Almugbel M, Tulbah M, Baradwan S, Alomar O. Abu-Zaid A, et al. Eur J Obstet Gynecol Reprod Biol. 2022 Sep;276:38-46. doi: 10.1016/j.ejogrb.2022.06.028. Epub 2022 Jul 3. Eur J Obstet Gynecol Reprod Biol. 2022. PMID: 35803111 Review.
OBJECTIVE: To conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated the efficacy and safety of isosorbide mononitrate (IMN) in promoting cervical ripening during labour induction. ...
OBJECTIVE: To conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated the efficacy and safet …
Isosorbide 5-mononitrate kinetics.
Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF. Major RM, et al. Clin Pharmacol Ther. 1984 May;35(5):653-9. doi: 10.1038/clpt.1984.90. Clin Pharmacol Ther. 1984. PMID: 6713775
The kinetics of isosorbide 5-mononitrate (5-ISMN) were studied in 12 healthy subjects after intravenous infusion and oral doses of 20 mg. ...
The kinetics of isosorbide 5-mononitrate (5-ISMN) were studied in 12 healthy subjects after intravenous infusion and or …
Isosorbide Mononitrate Versus Dinoprostone for Cervical Ripening During Labor Induction: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Abu-Zaid A, Khadawardi K, Al-Matary A, Alshahrani MS, Miski NT, Abuzaid M, Khalifa M, Almugbel M, Tulbah M, Baradwan S. Abu-Zaid A, et al. Reprod Sci. 2023 Feb;30(2):380-389. doi: 10.1007/s43032-022-00909-y. Epub 2022 Apr 19. Reprod Sci. 2023. PMID: 35441336 Review.
The objective of this study was to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated isosorbide mononitrate (ISMN) versus dinoprostone, a prostaglandin E2 (PGE2) analogue, in promoting cervical ripening during la …
The objective of this study was to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that evaluated …
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study.
Boettcher M, Mikus G, Trenk D, Düngen HD, Donath F, Werner N, Karakas M, Besche N, Schulz-Burck D, Gerrits M, Hung J, Becker C. Boettcher M, et al. Clin Transl Sci. 2022 May;15(5):1204-1214. doi: 10.1111/cts.13238. Epub 2022 Mar 17. Clin Transl Sci. 2022. PMID: 35299288 Free PMC article. Clinical Trial.
This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide mononitrate in patients with CCS. In this phase Ib, double-blind, multicenter study, patients were randomized 2:1 to receive vericig …
This study evaluated safety, tolerability, and the pharmacodynamic (PD) interaction between co-administered vericiguat and isosorbide
1,186 results